Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase III studies-Reference-Cited by-同舟云学术

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase III studies

Published:2013-05-21 Issue:7 Volume:67 Page:619-632
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Nitti V. W.¹,Khullar V.²,Kerrebroeck P.³,Herschorn S.⁴,Cambronero J.⁵,Angulo J. C.⁶,Blauwet M. B.⁷,Dorrepaal C.⁸,Siddiqui E.⁹¹⁰,Martin N. E.¹¹

Affiliation:

1. Department of Urology NYU Langone Medical Center New York NY USA

2. Urogynaecology Department St Mary's Hospital, Imperial College London UK

3. Department of Urology Maastricht University Medical Center Maastricht the Netherlands

4. Division of Urology University of Toronto Toronto ON Canada

5. Department of Urology Infanta Leonor Hospital Madrid Spain

6. Department of Urology Hospital Universitario De Getafe Madrid Spain

7. Astellas Pharma Global Development, Inc. Global Data Science – Biostatistics Northbrook IL USA

8. Astellas Pharma Global Development – EU, Global Medical Science – Urology Leiderdorp the Netherlands

9. Astellas Pharma Europe Ltd Surrey UK

10. Department of Urology Ealing Hospital London UK

11. Astellas Scientific and Medical Affairs Inc Northbrook IL USA

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.12194

Reference41 articles.

1. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

2. The overactive bladder: an overview for primary care health providers;Wein AJ;Int J Fertil Womens Med,1999

3. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study

4. Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatment

5. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The history of the pharmacologic treatment of urgency incontinence;Continence Reports;2024-09

2. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-03-18

3. Examining the Safety of Mirabegron: An Analysis of Real-World Pharmacovigilance Data from the US FDA Adverse Event Reporting System (FAERS) Database;2024-01-03

4. Comparison Of Outcome And Side Effects Profile Of Treatment Of Overactive Bladder With Different Classes Of Drugs;Journal of Rawalpindi Medical College;2023-12-30

5. Long-term beneficial effects of mirabegron in pediatric patients with therapy-refractory neurogenic lower urinary tract dysfunction;Journal of Pediatric Urology;2023-12